Briacell Therapeutics Corp Stock Price, News & Analysis

BriaCell Therapeutics (Nasdaq: BCTX) received a positive recommendation from the Data Safety Monitoring Board (DSMB) for its pivotal Phase 3 study of Bria-IMT™ plus immune checkpoint inhibitor in metastatic breast cancer. The DSMB, an independent expert group, completed its second safety data review and found no safety concerns, recommending the continuation of the ongoing study without modifications.

The study is being conducted under Fast Track Designation from the FDA. The company's management expressed satisfaction with the safety and tolerability profile of the Bria-IMT plus immune checkpoint inhibitor combination therapy, viewing the DSMB's recommendation as an encouraging sign for their novel immunotherapy approach to treating metastatic breast cancer.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) held its annual general meeting on February 5, 2025, for the fiscal year ended July 31, 2024. The meeting saw a 36.26% participation rate of issued and outstanding common shares. Shareholders strongly supported all proposed resolutions, including the re-appointment of MNP LLP as auditors and the election of board directors.

The elected board members, all receiving over 86% approval, include Dr. William V. Williams (88.42%), Mr. Jamieson Bondarenko (86.57%), Dr. Jane A. Gross (88.37%), Dr. Rebecca Taub (88.44%), Mr. Vaughn C. Embro-Pantalony (88.05%), and Mr. Martin E. Schmieg (87.99%).

BriaCell Therapeutics (Nasdaq: BCTX) has completed its previously announced best-efforts public offering, selling 762,500 common shares at $4.00 per share, raising gross proceeds of $3.05 million. The offering was conducted under the Company's effective shelf registration statement on Form S-3, with ThinkEquity serving as the sole placement agent.

The clinical-stage biotechnology company, which develops novel immunotherapies for cancer treatment, plans to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing its business objectives. The offering was executed under the TSX Company Manual Section 602.1 exemption, applicable to eligible interlisted issuers on recognized exchanges like Nasdaq.

BriaCell Therapeutics (Nasdaq: BCTX) has announced the pricing of a best-efforts public offering of 762,500 common shares at $4.00 per share, aiming to raise gross proceeds of $3.05 million. The offering is expected to close on February 5, 2025, subject to customary closing conditions.

The company plans to use the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives. ThinkEquity is serving as the sole placement agent for the offering, which is being conducted under a shelf registration statement on Form S-3 filed with the SEC on January 22, 2024, and declared effective on January 31, 2024.

The transaction is proceeding under the TSX Company Manual Section 602.1 exemption for eligible interlisted issuers on recognized exchanges like Nasdaq.

BriaCell Therapeutics (Nasdaq: BCTX) announced its intention to conduct a best-efforts public offering of common shares. The clinical-stage biotechnology company, which develops novel immunotherapies for cancer care, plans to use the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives.

The offering will be conducted under a shelf registration statement on Form S-3 filed with the SEC on January 22, 2024, and declared effective on January 31, 2024. ThinkEquity is serving as the sole placement agent. The company is utilizing the TSX Company Manual Section 602.1 exemption, which applies to eligible interlisted issuers on recognized exchanges like Nasdaq.

The completion, size, and terms of the offering remain subject to market conditions, with no guarantees provided regarding these aspects.

BriaCell Therapeutics (NASDAQ: BCTX) has announced remarkable results from their first patient treated with Bria-OTS™, their personalized off-the-shelf immunotherapy for metastatic breast cancer. The 78-year-old patient, who had previously failed multiple therapies, showed complete resolution of lung metastasis after just 2 months (4 doses) of treatment, with stable disease elsewhere.

The patient, enrolled on Nov 21, 2024, had extensive metastases in bone, lymph node, and lung. The treatment demonstrated excellent tolerability with no reported toxicity. This unprecedented result was achieved using the lowest dose level in the ongoing Phase 1/2a study.

The company is conducting a Phase 1/2a dose escalation study to evaluate Bria-OTS™ both as monotherapy and in combination with an immune checkpoint inhibitor. The study targets patients with recurrent metastatic breast cancer who have failed at least two prior systemic therapies.

BriaCell Therapeutics (Nasdaq: BCTX, BCTXW) has completed a 15:1 share consolidation on January 24, 2025, to maintain compliance with Nasdaq Capital Market listing requirements. The consolidation reduces the company's outstanding common shares from 44,204,061 to 2,946,940.

The post-consolidation shares will begin trading on both TSX and Nasdaq on January 29, 2025, under the same symbols 'BCT' and 'BCTX' respectively, with a new CUSIP number: 107930208. Fractional shares less than one-half have been cancelled, while those at least one-half have been rounded up to one whole share.

The exercise or conversion price of outstanding convertible securities has been proportionally adjusted. Shareholders with book shares will receive updated positions automatically, while those holding physical certificates must submit a Letter of Transmittal for the exchange.

BriaPro Therapeutics, a pre-clinical stage immunotherapy company, has announced alternative voting procedures for its upcoming annual general meeting scheduled for January 23, 2025, in Toronto. Due to a nationwide postal strike that began November 15, 2024, the company has made meeting materials available online through SEDAR+ and its website.

The meeting will cover financial statements review, director elections, and auditor appointment. Shareholders must vote by 10:30 a.m. EST on January 21, 2025. Registered shareholders can obtain voting control numbers through Computershare Shareholder Services, while beneficial shareholders have specific procedures based on their status as Objecting or Non-Objecting Beneficial Owners.

BriaCell Therapeutics Corp. (Nasdaq: BCTX) has announced alternative voting procedures for its upcoming annual general meeting on January 23, 2025, due to Canada's postal workers strike. The meeting materials are available on SEDAR+ and the company's website. The meeting will cover financial statements review, director elections, and auditor appointment.

Due to postal delays, shareholders are urged to vote before January 21, 2025, 10:00 AM EST. Registered shareholders can obtain voting control numbers via Computershare Shareholder Services. Beneficial shareholders, both NOBOs and OBOs, have specific procedures for accessing their voting materials and submitting votes through designated channels.